From Yahoo Finance: 2025-06-13 16:18:00

AbbVie Inc. (NYSE:ABBV) receives FDA approval to expand the use of Mavyret, an oral antiviral drug for Hepatitis C. The drug can now be used in adults and children aged three and older without cirrhosis. Treatment can be completed in eight weeks, based on Phase 3 study results.

AbbVie is an international biopharmaceutical company focused on developing advanced treatments for various health conditions. The company’s areas of concentration include immunology, cancer, neuroscience, eye care, and aesthetics. AbbVie aims to improve lives by researching, developing, and providing new therapies for serious medical needs lacking effective solutions.



Read more at Yahoo Finance: AbbVie Secures FDA Approval to Expand Mavyret’s Label